CervoMed (CRVO) Projected to Post Earnings on Tuesday

CervoMed (NASDAQ:CRVO) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect CervoMed to post earnings of ($0.60) per share and revenue of $1.70 million for the quarter.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The firm had revenue of $2.16 million during the quarter, compared to the consensus estimate of $1.51 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Stock Performance

NASDAQ:CRVO opened at $8.44 on Friday. The firm has a market cap of $73.45 million, a P/E ratio of -4.16 and a beta of -0.23. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $25.67. The firm has a 50-day simple moving average of $8.63 and a two-hundred day simple moving average of $6.50.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Chardan Capital upgraded shares of CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Thursday, March 13th. Jones Trading upgraded CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Thursday, March 13th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of CervoMed in a research report on Wednesday, March 26th. Brookline Capital Management raised CervoMed from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. Finally, Roth Mkm upped their target price on shares of CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $27.50.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.